APA (7th ed.) Citation

Dong Z, Wang Y, Guo J, Tian C, Pan W, Wang H, & Yan J. (2022). Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in vivo Anti-Tumor Activity. Dove Medical Press.

Chicago Style (17th ed.) Citation

Dong Z, Wang Y, Guo J, Tian C, Pan W, Wang H, and Yan J. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in Vivo Anti-Tumor Activity. Dove Medical Press, 2022.

MLA (9th ed.) Citation

Dong Z, et al. Prostate Cancer Therapy Using Docetaxel and Formononetin Combination: Hyaluronic Acid and Epidermal Growth Factor Receptor Targeted Peptide Dual Ligands Modified Binary Nanoparticles to Facilitate the in Vivo Anti-Tumor Activity. Dove Medical Press, 2022.